Please ensure Javascript is enabled for purposes of website accessibility

Fauci Warns of Rushing Coronavirus Vaccine Onto the Market

By Eric Volkman – Aug 25, 2020 at 5:08PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There are numerous dangers in getting a vaccine out before it's been properly researched and evaluated.

Addressing concerns that the development of coronavirus vaccines for COVID-19 could be hurried due to politics, Dr. Anthony Fauci cautioned that their development should not be rushed.

In an interview with Reuters published on Monday, Fauci -- the director of the government's National Institute of Allergy and Infectious Diseases (NIAID) -- said that "[t]he one thing that you would not want to see with a vaccine is getting an EUA (emergency use authorization) before you have a signal of efficacy."

His comments came a day after the Food and Drug Administration (FDA) granted an EUA for the use of convalescent plasma to treat COVID-19. That authorization is controversial because the data is not supported by robust clinical testing.

Gloved hands filling a syringe from a vial.

Image source: Getty Images.

There is also growing concern that the current presidential administration will exert pressure on the FDA to approve a vaccine candidate prior to the Nov. 3 election.

Among other risks, approving a vaccine before it has been fully and properly researched could badly affect the prospects for candidates still in development. "One of the potential dangers if you prematurely let a vaccine out is that it would make it difficult, if not impossible, for the other vaccines to enroll people in their trial," said Fauci.

Several promising vaccine candidates are now in late-stage clinical trials. However, it is unlikely that the process for any of them will wrap up before the election. Moderna (MRNA -0.29%) is arguably the most prominent of these; its mRNA-1273 has demonstrated high efficacy in earlier phases of testing. The Moderna candidate is the leader among messenger RNA-based solutions for a coronavirus vaccine.

The share performances of companies currently testing such vaccine candidates were mixed on Tuesday. Moderna was among the gainers, rising 2.1% on the day to eclipse the 0.4% increase of the S&P 500 index.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Moderna Stock Quote
Moderna
MRNA
$180.96 (-0.29%) $0.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.